Back to News
Market Impact: 0.2
Bausch Health Broadens Access To Long-Acting Schizophrenia Treatment In Canada
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Bausch Health Canada, a subsidiary of Bausch Health Companies, announced expanded public reimbursement in Canada for PrOKEDI 75 mg and 100 mg, an extended-release risperidone injection for adults with schizophrenia. The article provides no reimbursement details or financial impact estimates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BHC0.45
More News
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Walmart’s Flipkart is quietly building a food delivery challenger in India
- Credit stress is threatening to unwind the AI bull. All eyes are on Oracle to hold the line
- LightStream stops accepting loan applications. Try these 6 lenders instead
- Ciena EVP DiPerna sells $308,865 in CIEN stock